Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics' stock has experienced significant events in the past six months. The share price was $13.78 as of May 4, 2026, a 174.50% increase from May 5, 2025. Positive Phase 2 trial results for abdakibart in hidradenitis suppurativa have driven valuation. A $375 million public offering was announced in May 2026 to advance abdakibart's clinical development. Several analyst firms have issued positive reports and increased their price targets for AVTX. Avalo Therapeutics insiders have sold approximately $2,501,346.00 in company stock in the past 90 days. The company reported quarterly earnings data, with ($0.37) EPS for the quarter, topping analysts' estimates of ($1.54).

Avalo Therapeutics, Inc. does not experience traditional demand seasonality. The demand for its therapies is primarily driven by the progression of its clinical trials, regulatory approvals, and the underlying prevalence and unmet medical needs of the diseases it aims to treat. Success in clinical trials and subsequent market approval would dictate the demand for its products, rather than seasonal fluctuations.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases, particularly IL-1β-based treatments. Their lead asset, AVTX-009 (abdakibart), is in Phase 2 clinical trials for inflammatory diseases like hidradenitis suppurativa. The company's pipeline includes quisovalimab, AVTX-008, AVTX-006, and AVTX-913. Founded in 2011, the company was formerly known as Cerecor Inc. and changed its name in August 2021.

Avalo Therapeutics, Inc. is headquartered in Wayne, Pennsylvania, United States, and focuses on developing therapies for treatment in the United States.

Avalo Therapeutics' brand reputation in the past year appears to be largely positive, driven by favorable clinical trial results and strong analyst sentiment. The positive topline data from the Phase 2 LOTUS study for AVTX-009 in hidradenitis suppurativa has bolstered the company's standing. This success has led to multiple analyst upgrades and increased price targets. The company's focus on developing treatments for unmet medical needs in immune-mediated inflammatory diseases also contributes to a positive perception.

Avalo Therapeutics, Inc. has a significant institutional ownership presence, with 89 institutional owners and shareholders holding a total of 19,476,691 shares, accounting for 87.26% of the stock. Avalo Therapeutics insiders hold 356.84%, and retail investors hold 0.00%. BVF Inc/il, Nantahala Capital Management, LLC and Orbimed Advisors Llc are major institutional owners. Armistice Capital LLC is the largest individual shareholder, owning 51.62 million shares, representing 226.50% of the company.